Michael Schmidt

just curious how you think about either potentially pursuing other registration opportunities in PDA perhaps with investigational therapies such as pan-RAS inhibitors

help us understand how you're thinking about the overall opportunity for Monjuvi in this setting and just positioning versus Polyvi

are there specific areas where you think Incyte is underinvested, be it in terms of targets, modalities or disease areas

Did you observe a similar trajectory also for the high score seventy-five outcomes?

can you talk a bit more about your expectations for how much of that is driven going forward by new patients versus continued, you know, use of the drug

Can you set some expectations for the upcoming Phase 3 in prurigo nodularis? What's the clinical bar here given there's no topical therapies available?